Literature DB >> 1850705

Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

J F Woessner1.   

Abstract

Matrix metalloproteinases are an important group of zinc enzymes responsible for degradation of the extracellular matrix components such as collagen and proteoglycans in normal embryogenesis and remodeling and in many disease processes such as arthritis, cancer, periodontitis, and osteoporosis. A matrixin family is defined, comprising at least seven members that range in size from Mr 28,000 to 92,000 and are related in gene sequence to collagenase. All family members are secreted as zymogens that lose peptides of about 10,000 daltons upon activation. Latency is due to a conserved cysteine that binds to zinc at the active center. Latency is overcome by physical (chaotropic agents), chemical (HOCl, mercurials), and enzymatic (trypsin, plasmin) treatments that separate the cysteine residue from the zinc. Expression of the metalloproteinases is switched on by a variety of agents acting through regulatory elements of the gene, particularly the AP-1 binding site. A family of protein inhibitors of Mr 28,500 or less binds strongly and stoichiometrically in noncovalent fashion to inhibit members of the family. The serum protein alpha 2-macroglobulin and relatives are also strongly inhibitory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850705

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  532 in total

1.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.

Authors:  Y Jo; J Yeon; H J Kim; S T Lee
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Structure of a rat α₁-macroglobulin receptor-binding domain dimer.

Authors:  T Xiao; D L DeCamp; S R Sprang
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

3.  The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer.

Authors:  K Mizutani; K Kofuji; K Shirouzu
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

4.  Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis.

Authors:  A Stallmach; C C Chan; K W Ecker; G Feifel; H Herbst; D Schuppan; M Zeitz
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

5.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 6.  Matrix metalloproteinase inhibitors in rheumatic diseases.

Authors:  D R Close
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

7.  Morphological and molecular characterization of human hamstrings shows that tendon features are not influenced by donor age.

Authors:  Nicoletta Gagliano; Alessandra Menon; Federico Cabitza; Riccardo Compagnoni; Pietro Randelli
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-08-02       Impact factor: 4.342

8.  Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1).

Authors:  H Nagase; K Suzuki; T E Cawston; K Brew
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

9.  Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis.

Authors:  Y Friedmann; I Vlodavsky; H Aingorn; A Aviv; T Peretz; I Pecker; O Pappo
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

10.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.